Berlin - Delayed Quote EUR

Apellis Pharmaceuticals Inc (1JK.BE)

15.37

-0.00

(-0.01%)

At close: April 25 at 9:52:10 PM GMT+2

Is Apellis Pharmaceuticals, Inc. (APLS) Among the Best Guru Stocks to Buy According to Wall Street Analysts?

We recently published a list of 11 Best Guru Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stands against other Guru stocks to invest in. Wall Street seems to be breathing a little easier after the initial panic over […]

Insider Monkey 3 days ago

APLS
Apellis Announces Craig Wheeler to Join the Board of Directors

WALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that Craig Wheeler, founder and chief executive officer of Headwaters Biotech Advisors, will join the Apellis Board of Directors, effective immediately. Mr. Wheeler is a highly accomplished executive with more than 30 years of leadership experience across the biopharmaceutical industry. “We are thrilled to welcome Craig to the Apellis Board of Directors,” said Cedric Francois, M.D., Ph

GlobeNewswire 5 days ago

APLS
BioHarvest Sciences Inc. (BHST) Soars 5.2%: Is Further Upside Left in the Stock?

BioHarvest Sciences Inc. (BHST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks 11 days ago

APLS
APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag

The FDA accepts Apellis' sNDA seeking label expansion of Empaveli to treat two rare kidney diseases for review under the Priority Review pathway.

Zacks 24 days ago

APLS

NVS
FDA accepts priority review of Apellis’ Empaveli sNDA for kidney diseases

The sNDA application is based on the positive outcomes from the Phase III VALIANT trial at week 26.

Pharmaceutical Technology 24 days ago

APLS
Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

PDUFA target action date is July 28, 2025 WALTHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review designation of the supplemental New Drug Application (sNDA) for EMPAVELI® (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are severe and rare kidney diseases. The Prescription

GlobeNewswire 25 days ago

APLS
Exploring US High Growth Tech Stocks In March 2025

In the United States, the market has experienced a 3.5% decline over the last week, yet it remains up by 5.8% over the past year with earnings expected to grow annually by 14%. In this context of fluctuating yet optimistic growth prospects, identifying high-growth tech stocks involves focusing on companies that demonstrate robust innovation and adaptability in response to evolving market dynamics.

Simply Wall St. 26 days ago

ENFN

CMRX

APLS
Is Apellis Pharmaceuticals, Inc. (APLS) a Promising Biotech Stock According to Wall Street Analysts

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we are going to look at where Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stands against other biotech stocks. Biotech Sector Set for Growth Amid Innovation and Investor Interest The biotechnology sector is gaining new momentum with better […]

Insider Monkey last month

APLS
Morgan Stanley says Fabhalta’s label leaves opportunity for Apellis’ Empaveli

Morgan Stanley analyst Judah Frommer notes that Novartis (NVS) has received FDA approval for Fabhalta for C3G. The label comes with a few important restrictions/caveats that leave room for Apellis’s (APLS) Empaveli to differentiate itself. The firm highlights that Fabhalta is indicated for adults with C3G, and is indicated to reduce proteinuria. Moreover, the label explicitly states that outcomes have not been established in post-transplant patients. Morgan Stanley says that overall, the restric

TipRanks last month

NVS

NVSEF

APLS
Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst

Last week, Apellis Pharmaceuticals Inc (NASDAQ:APLS) reported a fourth-quarter earnings loss of 29 cents per share, beating the consensus loss of 37 cents. Sales increased 45.2% to $212.5 million, beating the consensus of $198.35 million. JP Morgan maintains the Overweight rating with a price forecast of $54. Analyst Anupam Rama says Apellis’ lead asset, pegcetacoplan (Syfovre/Empaveli), represents a differentiated asset in the complement space, with opportunities across ophthalmology, hematolog

Benzinga last month

APLS
Apellis Q4 Loss Narrower Than Expected, Syfovre Sales Drive Revenues

APLS reports better-than-expected fourth-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong sales of Syfovre.

Zacks last month

APLS
Apellis Pharmaceuticals Full Year 2024 Earnings: Beats Expectations

Apellis Pharmaceuticals ( NASDAQ:APLS ) Full Year 2024 Results Key Financial Results Revenue: US$781.4m (up 97% from FY...

Simply Wall St. last month

APLS
Apellis Pharmaceuticals Inc (APLS) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and ...

Apellis Pharmaceuticals Inc (APLS) reports significant revenue growth driven by SYFOVRE, while navigating market challenges and advancing its development pipeline.

GuruFocus.com last month

APLS
Q4 2024 Apellis Pharmaceuticals Inc Earnings Call

Q4 2024 Apellis Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents last month

APLS
Compared to Estimates, Apellis Pharmaceuticals (APLS) Q4 Earnings: A Look at Key Metrics

Although the revenue and EPS for Apellis Pharmaceuticals (APLS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks last month

APLS
Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Tops Revenue Estimates

Apellis Pharmaceuticals (APLS) delivered earnings and revenue surprises of 25.64% and 8.46%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

APLS
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Reported $781.4 million in full year 2024 revenues, representing 97% year-over-year growth SYFOVRE® (pegcetacoplan injection) full year 2024 net product revenue of $611.9 millionEMPAVELI® (pegcetacoplan) full year 2024 net product revenue of $98.1 million Submitted a supplemental new drug application (sNDA) for approval of EMPAVELI for C3G and primary IC-MPGN; U.S. launch anticipated in 2H 2025, if approved On track to initiate two Phase 3 trials of EMPAVELI in focal segmental glomerulosclerosis

GlobeNewswire last month

APLS
Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

YmAbs Therapeutics (YMAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks last month

YMAB

APLS
Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 10:30 a.m. ET. The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 90 days following the event. About ApellisApellis Pharmaceu

GlobeNewswire last month

APLS
Why Apellis Pharmaceuticals, Inc. (APLS) is the Most Oversold Pharma Stock to Buy According to Analysts

We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts. In this article, we are going to take a look at where Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stands against the other oversold pharma stocks to buy according to analysts. On February 20, Emily Field, Head of European Pharma Research at […]

Insider Monkey 2 months ago

APLS

Performance Overview

Return	1JK.BE	S&P 500 (^GSPC)
YTD	-50.64%	-6.06%
1-Year	-65.75%	+9.44%
3-Year	-66.69%	+28.61%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Apellis Pharmaceuticals Inc (1JK.BE)

Is Apellis Pharmaceuticals, Inc. (APLS) Among the Best Guru Stocks to Buy According to Wall Street Analysts?

Apellis Announces Craig Wheeler to Join the Board of Directors

BioHarvest Sciences Inc. (BHST) Soars 5.2%: Is Further Upside Left in the Stock?

APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag

FDA accepts priority review of Apellis’ Empaveli sNDA for kidney diseases

Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

Exploring US High Growth Tech Stocks In March 2025

Is Apellis Pharmaceuticals, Inc. (APLS) a Promising Biotech Stock According to Wall Street Analysts

Morgan Stanley says Fabhalta’s label leaves opportunity for Apellis’ Empaveli

Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst

Apellis Q4 Loss Narrower Than Expected, Syfovre Sales Drive Revenues

Apellis Pharmaceuticals Full Year 2024 Earnings: Beats Expectations

Apellis Pharmaceuticals Inc (APLS) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and ...

Q4 2024 Apellis Pharmaceuticals Inc Earnings Call

Compared to Estimates, Apellis Pharmaceuticals (APLS) Q4 Earnings: A Look at Key Metrics

Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Tops Revenue Estimates

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

Why Apellis Pharmaceuticals, Inc. (APLS) is the Most Oversold Pharma Stock to Buy According to Analysts

Performance Overview